← Leaderboards
Yang Liu
Ohio State University
$21,443,530
Attributed
$27,372,043
Total exposure
16
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–20$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$26,386,611 · 15
FDA$985,432 · 1
By mechanism
R01$20,773,979 · 11
R44$2,999,396 · 1
U01$2,275,605 · 1
T32$717,920 · 1
R21$440,500 · 1
R41$164,643 · 1
Top collaborators
- Pan Zheng8 shared
- Sami Nimer Malek5 shared
- Reuven J Schore4 shared
- Martin Devenport3 shared
- Pavan Reddy2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Ming You$26,875,453
- Nicholas C Denko$10,501,039
- Pan Zheng$7,391,253
- Jane Elizabeth Jackman$6,635,073
- Saame R Shaikh$6,682,858
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMutationMolecularMediatingMalignant NeoplasmsResponseAutoimmune DiseasesLinkT-LymphocyteReceptorAdultMouse ModelLeukocyte Activation /TransformationTherapeutic EffectImmunePreventCytotoxic T LymphocyteClinical TrialsPublic Health RelevanceFundingGenesGeneticLeadLaboratory Mouse
Grant awards (78)
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients$1,000,000
R44 · FY2020 · CA
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$985,075
R44 · FY2020 · CA
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)$485,432
R01 · FY2020 · FD · contact PI
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse$1,014,321
R44 · FY2019 · CA
Checkpoints in the cellular response to tissue injury$427,019
R01 · FY2019 · AI · contact PI
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)$500,000
R01 · FY2018 · FD · contact PI
Checkpoints in the cellular response to tissue injury$427,019
R01 · FY2018 · AI · contact PI
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML$521,464
U01 · FY2017 · CA · contact PI
Checkpoints in the cellular response to tissue injury$475,387
R01 · FY2017 · AI · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$463,347
R01 · FY2017 · CA · contact PI
Checkpoints in the cellular response to tissue injury$475,387
R01 · FY2016 · AI · contact PI
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML$472,123
U01 · FY2016 · CA · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$463,347
R01 · FY2016 · CA · contact PI
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML$628,352
U01 · FY2015 · CA · contact PI
Checkpoints in the cellular response to tissue injury$475,387
R01 · FY2015 · AI · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$463,347
R01 · FY2015 · CA · contact PI
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML$653,666
U01 · FY2014 · CA · contact PI
CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study$534,084
R01 · FY2014 · NS · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$447,360
R01 · FY2014 · CA · contact PI
CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study$546,203
R01 · FY2013 · NS · contact PI
Targeted Elimination of Cancer Stem Cells for AML Therapy$479,195
R01 · FY2013 · CA · contact PI
Checkpoints of Host Response to Cellular Injuries$396,157
R01 · FY2013 · AI · contact PI
CD24 in Cancer Resistance and Immunotherapy$296,549
R01 · FY2013 · CA · contact PI
Checkpoints of Host Response to Cellular Injuries$307,727
R01 · FY2012 · AI · contact PI
CD24 in Cancer Resistance and Immunotherapy$283,379
R01 · FY2012 · CA · contact PI
Checkpoints of Host Response to Cellular Injuries$72,362
R01 · FY2012 · AI · contact PI
Checkpoints of Host Response to Cellular Injuries$468,150
R01 · FY2011 · AI · contact PI
CD24 in Cancer Resistance and Immunotherapy$283,379
R01 · FY2011 · CA · contact PI
Checkpoints of Host Response to Cellular Injuries$376,831
R01 · FY2010 · AI · contact PI
FoxP3 as the X-Linked Breast Cancer Suppressor Gene$326,913
R01 · FY2010 · CA · contact PI
CD24 in Cancer Resistance and Immunotherapy$292,144
R01 · FY2010 · CA · contact PI
Selective Modulation of Cancer Immunity and Autoimmunity$259,217
R01 · FY2010 · CA · contact PI
Checkpoints of Host Response to Cellular Injuries$231,149
R01 · FY2010 · AI · contact PI
Checkpoints of Host Response to Cellular Injuries$380,800
R01 · FY2009 · AI · contact PI
FoxP3 as the X-Linked Breast Cancer Suppressor Gene$321,560
R01 · FY2009 · CA · contact PI
FoxP3 as the X-Linked Breast Cancer Suppressor Gene$304,163
R01 · FY2009 · CA · contact PI
CD24 in Cancer Resistance and Immunotherapy$292,144
R01 · FY2009 · CA · contact PI
Selective Modulation of Cancer Immunity and Autoimmunity$259,298
R01 · FY2009 · CA · contact PI
Checkpoints for homeostatsis and autoimmune diseases$354,125
R01 · FY2008 · AI · contact PI
FoxP3 as the X-Linked Breast Cancer Suppressor Gene$313,248
R01 · FY2008 · CA · contact PI
Selective Modulation of Cancer Immunity and Autoimmunity$259,376
R01 · FY2008 · CA · contact PI
Checkpoints for homeostatsis and autoimmune diseases$361,409
R01 · FY2007 · AI · contact PI
Costimulation and Significance of Negative Selection$329,557
R01 · FY2007 · AI · contact PI
FoxP3 as the X-Linked Breast Cancer Suppressor Gene$310,612
R01 · FY2007 · CA · contact PI
CD24 Polymorphism and multiple sclerosis$299,957
R01 · FY2007 · NS · contact PI
Selective Modulation of Cancer Immunity and Autoimmunity$259,452
R01 · FY2007 · CA · contact PI
Checkpoints for homeostatsis and autoimmune diseases$372,616
R01 · FY2006 · AI · contact PI
Costimulation and Significance of Negative Selection$324,077
R01 · FY2006 · AI · contact PI
Selective Modulation of Cancer Immunity and Autoimmunity$265,363
R01 · FY2006 · CA · contact PI
Tumor burden and T cell immunity$239,676
R01 · FY2006 · CA · contact PI
CD24 Polymorphism and multiple sclerosis$191,007
R01 · FY2006 · NS · contact PI
CD24 Polymorphism and multiple sclerosis$112,829
R01 · FY2006 · NS · contact PI
Tumor burden and T cell immunity$35,681
R01 · FY2006 · CA · contact PI
Costimulation and Significance of Negative Selection$331,875
R01 · FY2005 · AI
CD24 Polymorphism and multiple sclerosis$311,147
R01 · FY2005 · NS
Tumor burden and T cell immunity$277,300
R01 · FY2005 · CA
Tumor Immunology$168,556
T32 · FY2005 · CA
Costimulation and Significance of Negative Selection$331,875
R01 · FY2004 · AI
CD24 Polymorphism and multiple sclerosis$311,147
R01 · FY2004 · NS
Tumor burden and T cell immunity$277,300
R01 · FY2004 · CA
Tumor Immunology$207,033
T32 · FY2004 · CA
B7 RECEPTORS, TUMOR IMMUNOTHERAPY AND IMMUNE REGULATION$414,623
R01 · FY2003 · CA
Costimulation and Significance of Negative Selection$331,875
R01 · FY2003 · AI
Tumor burden and T cell immunity$277,300
R01 · FY2003 · CA
Tumor Immunology$223,152
T32 · FY2003 · CA
Tumor Immunology$20,709
T32 · FY2003 · CA
B7 RECEPTORS, TUMOR IMMUNOTHERAPY AND IMMUNE REGULATION$409,313
R01 · FY2002 · CA
Tumor burden and T cell immunity$277,300
R01 · FY2002 · CA
Tumor Immunology$98,470
T32 · FY2002 · CA
RESPONSE AND TOLERANCE TO AN UNMUTATED TUMOR ANTIGEN PIA$243,252
R01 · FY2001 · CA
B7 RECEPTORS, TUMOR IMMUNOTHERAPY AND IMMUNE REGULATION$231,525
R01 · FY2001 · CA
COSTIMULATION FOR MEMORY AND EFFECTOR T CELLS$221,320
R01 · FY2001 · AI
OPTIMAL DELIVERY OF TWO SIGNALS TO ENHANCE ANTI-HIV CTL$220,500
R21 · FY2001 · AI
Human gene knock-in mice and anti-cancer antibodies$164,643
R41 · FY2001 · CA
RESPONSE AND TOLERANCE TO AN UNMUTATED TUMOR ANTIGEN PIA$237,006
R01 · FY2000 · CA
B7 RECEPTORS, TUMOR IMMUNOTHERAPY AND IMMUNE REGULATION$231,525
R01 · FY2000 · CA
OPTIMAL DELIVERY OF TWO SIGNALS TO ENHANCE ANTI-HIV CTL$220,000
R21 · FY2000 · AI
COSTIMULATION FOR MEMORY AND EFFECTOR T CELLS$214,875
R01 · FY2000 · AI